Upon successful completion of the business combination, Immatics will receive up to approximately $148 million of cash held within Arya’s trust account. Leading institutional investors commit $104 million of cash through a common stock private investment in public equity (“PIPE”) led by Perceptive Advisors and other top-tier US healthcare investors. Immatics shareholders, Arya shareholders and PIPE investors will hold shares in the newly formed company with the name Immatics N.V. that is expected to be listed on NASDAQ under the ticker symbol “IMTX”. Business combination completion is expected in the second quarter of 2020
Immatics Announces Business Combination with Arya Sciences
Allecra Therapeutics Announces Positive Top-Line Results for Phase 3
Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP® for Complicated Urinary Tract Infection. EXBLIFEP demonstrated superiority in the primary endpoint of clinical cure and microbiological eradication at test-of-cure over piperacillin-tazobactam.
Immatics and GSK Partner to Develop Novel Adoptive Cell Therapies
Immatics Biotechnologies GmbH today announced it has entered into a strategic collaboration agreement with GSK to develop novel adoptive cell therapies targeting multiple cancer indications.